Research Paper Volume 14, Issue 19 pp 7941—7958
ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancer
Figure 4. Relationship between expression of ERAP2 and sensitivity to gemcitabine in pancreatic cancer. (A) Correlation between the expression value of ERAP2 in GDSC1 and GDSC2 pancreatic cancer cell lines and the IC50 value of gemcitabine. (B) Expression of ERAP2 in two types of pancreatic cancer fibroblasts. (C) Relationship between the effect of gemcitabine treatment and ERAP2 expression in TCGA pancreatic cancer patients.